A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults

Article ID	Journal	Published Year	Pages	File Type
10963087	Vaccine	2016	7 Pages	PDF

Abstract

This safety study, the largest randomized, active-controlled trial evaluating a recombinant MnB vaccine, demonstrated that bivalent rLP2086 is safe and tolerable in healthy individuals â¥10 to <26 years of age.

Keywords

IMD SAE HAV MNB fHBP Neisseria meningitidis serogroup B Bivalent rLP2086 Safety MAE Invasive meningococcal disease adverse event Serious adverse event Meningitis Adolescents Vaccine Factor H binding protein

Related Topics

Life Sciences Immunology and Microbiology Immunology

Preview

A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults

Authors

Lars Ostergaard, Gregg H. Lucksinger, Judith Absalon, Johannes Beeslaar, Joseph Eiden, Kathrin U. Jansen, Laura J. York, Angela Quinn, Mette E. Graversen, John L. Perez,